๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Breast cancer chemoprevention trials using the fine-needle aspiration model

โœ Scribed by Bruce F. Kimler; Carol J. Fabian; Dennis D. Wallace

Publisher
John Wiley and Sons
Year
2000
Tongue
English
Weight
92 KB
Volume
77
Category
Article
ISSN
0730-2312

No coin nor oath required. For personal study only.

โœฆ Synopsis

Selection of surrogate endpoint biomarkers (SEBs) and appropriate study design are two of the main challenges in evaluating potential chemopreventive agents. In a prospective random fine-needle aspiration (FNA) study of women at high risk of development of breast cancer, we previously demonstrated that cytologic evidence of epithelial hyperplasia with or without atypia, as well as abnormalities of several cellular biomarkers (DNA ploidy; immunocytochemical expression of p53, EGFR, ER, and/or Her-2/neu), were more prevalent in high-risk women than in low-risk controls. We also demonstrated that the subsequent development of breast cancer was best predicted by an initial presentation of hyperplasia with atypia, as well as by multiple biomarker abnormalities. These findings indicate that FNA cytology and biomarkers can be used to identify women who are appropriate subjects for chemoprevention trials, and can then be used as surrogate endpoint biomarkers to monitor efficacy of potential agents. An example of this use in an ongoing single-agent phase II trial is provided. Several options for study design of possible multi-agent breast cancer chemoprevention trials are discussed, depending upon the existing preclinical and clinical data, the questions being asked, and the number of eligible subjects available.

๐Ÿ“œ SIMILAR VOLUMES

Breast cytology and biomarkers obtained
Breast cytology and biomarkers obtained by random fine needle aspiration: Use in risk assessment and early chemoprevention trials
โœ Fabian, Carol J.; Zalles, Carola; Kamel, Sahar; Zeiger, Sandy; Simon, Connie; Ki ๐Ÿ“‚ Article ๐Ÿ“… 1997 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 138 KB

In a prospective pilot study, we performed breast fine needle aspirations (FNAs) on 224 high-risk and 30 low-risk women and analyzed these aspirates for cytologic changes and biomarker abnormalities of aneuploidy and overexpressed estrogen receptor (ER), epidermal growth factor receptor (EGFR), p53

The uniform approach to breast fine-need
The uniform approach to breast fine-needle aspiration biopsy
โœ National Cancer Institute Fine-Needle Aspiration of Breast Workshop Subcommittee ๐Ÿ“‚ Article ๐Ÿ“… 1997 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 126 KB ๐Ÿ‘ 2 views

Recommendations Indications I. Indications for performance of fine-needle aspiration (FNA) or core biopsies in palpable breast lesions A. Sufficiently defined palpable breast masses of clinical or patient concern should be aspirated regardless of imaging findings where experienced FNA services are a

Use of fine needle aspiration cytology w
Use of fine needle aspiration cytology with immediate reporting in the diagnosis of breast disease
โœ S. Nicholson; J. R. C. Sainsbury; V. Wadehra; G. K. Needham; J. R. Farndon ๐Ÿ“‚ Article ๐Ÿ“… 1988 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 449 KB ๐Ÿ‘ 1 views

## Fine needle aspiration biopsy for cytological examination ( F N A C ) is becoming increasingly accepted as a means of tissue diagnosis in breast disease. This study examines the feasibility and accuracy of FNAC in 'immediate reporting' by a consultant cytopathologist in a busy breast clinic. Ov

Use of fine-needle aspiration biopsy in
Use of fine-needle aspiration biopsy in the evaluation of splenic lesions in a cancer center
โœ Nancy P. Caraway; Christina V. Fanning ๐Ÿ“‚ Article ๐Ÿ“… 1997 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 159 KB ๐Ÿ‘ 2 views

Fine-needle aspiration biopsy (FNAB) of the spleen was performed on 50 patients, of whom 40 had had a previous diagnosis of malignancy (23 lymphoproliferative disorders, 13 carcinomas, 3 melanomas, and 1 sarcoma). The cytologic diagnoses included 22 cases positive for malignancy (10 lymphomas, 9 met